The Mechanism and Prognosis of Pulmonary Circulation Dysfunction
The Mechanism and Prognosis of Pulmonary Circulation Dysfunction in Pulmonary Injury and Recovery
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jianguo He, MD
- Phone Number: 80-10-88398060
- Email: hejianguofw@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100037
- Recruiting
- Cardiovascular Institute and Fu Wai Hospital
-
Contact:
- Jianguo He, MD
- Phone Number: 86 01088398060
- Email: hejianguofw@163.com
-
Principal Investigator:
- Jianguo He, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Chinese Han population older than 14 years old
- Acute VTE patients diagnosed in 1 month
- With informed consent
Exclusion Criteria:
- Patients with psychosis
- Patients with contraindications for computed tomographic pulmonary angiography (CTPA)
- Chronic VTE
- Recurrence of chronic VTE
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All cause death
Time Frame: 6 months
|
death
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Venous thromboembolism (VTE) recurrence
Time Frame: 6months
|
VTE recurrence detected by echocardiography or CTPA scan
|
6months
|
|
chronic thromboembolism pulmonary hypertension(CTEPH)
Time Frame: 6 months
|
newly developed CTEPH detected by pulmonary angiography
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- 2017-I2M-1-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on VTE
-
NCT03251482CompletedVTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
-
NCT06831474RecruitingBreastfeeding | Postpartum | Breast Milk Collection | Rivaroxaban | VTE Prophylaxis | VTE (Venous Thromboembolism)
-
NCT07310693RecruitingVenous Thromboembolism (VTE) | Occult Cancer
-
NCT07228663Not yet recruitingVenous Thromboembolism (VTE) | Hip Fracture Surgery | Cardiovascular Prevention
-
NCT07015905RecruitingVenous Thromboembolism (VTE)
-
NCT06057844RecruitingVenous Thromboembolism (VTE)
-
NCT03802929RecruitingVenous Thromboembolism (VTE)
-
NCT04141228Completed
-
NCT07005024RecruitingCancer | VTE (Venous Thromboembolism)